Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

被引：4
|
作者：
Adib, Elio [1 ]
Jain, Rohit K. [2 ]
Skelton, William Paul [3 ]
Freeman, Dory [1 ]
Curran, Catherine [1 ]
Akl, Elie W. [4 ]
Nassar, Amin [4 ]
Ravi, Praful [1 ]
Mantia, Charlene [1 ]
Merchan, Jaime R. [5 ]
Tan, Winston [6 ]
Plastini, Trisha M. [7 ]
Choueiri, Toni K. [1 ,8 ]
Sonpavde, Guru [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Univ Miami, Miami, FL USA
[6] Mayo Clin Hosp, Jacksonville, FL USA
[7] Univ Penn Hlth Syst, Philadelphia, PA USA
[8] Harvard Med Sch, Boston, MA 02115 USA
[9] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
472
引用
收藏
页数：3
相关论文
共 50 条
  • [1] FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
    Adib, Elio
    El-Zarif, Talal
    Jain, Rohit K.
    Skelton, William P., IV
    Freeman, Dory
    Curran, Catherine
    Akl, Elie W.
    Nassar, Amin H.
    Ravi, Praful
    Mantia, Charlene
    Kwiatkowski, David J.
    Choueiri, Toni K.
    Sonpavde, Guru P.
    BJUI COMPASS, 2022, 3 (02): : 169 - 172
  • [2] Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    Nagata, Yujiro
    Minato, Akinori
    Aono, Hisami
    Kimuro, Rieko
    Higashijima, Katsuyoshi
    Tomisaki, Ikko
    Harada, Kenichi
    Miyamoto, Hiroshi
    Fujimoto, Naohiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (19)
  • [3] Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.
    Saliby, Renee Maria
    Semaan, Karl
    Epstein, Ilana B.
    Liria, Sonsoles
    Dall, Christopher
    Saad, Eddy
    Eid, Marc
    Canniff, John
    Kwak, Lucia
    Berg, Stephanie A.
    Mantia, Charlene
    McGregor, Bradley Alexander
    Braun, David A.
    Choueiri, Toni K.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
    Jain, Rohit K.
    Kim, Youngchul
    Rembisz, Jennifer
    Piekarz, Richard
    Synold, Timothy W.
    Zhang, Jingsong
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).
    Jain, Rohit K.
    Heiligh, Jazlyn
    Kim, Youngchul
    Piekarz, Richard
    Pelosof, Lorraine Cheryl
    Yang, Yuanquan
    D'souza, Anishka
    Wong, Risa Liang
    Graham, Laura
    Gupta, Sumati
    Park, Anna
    Synold, Timothy W.
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 625 - 625
  • [6] Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
    Teo, Min Yuen
    Ratna, Neha
    Regazzi, Ashley Marie
    Zimmerman, Danielle Elise
    McHugh, Deaglan Joseph
    Laccetti, Andrew Leonard
    Xiao Han
    Lee, Chung-Han
    Aggen, David Henry
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] FGFR2/3 in urothelial carcinoma
    Rose, Michael
    Gaisa, Nadine T.
    PATHOLOGIE, 2024, 45 (06): : 409 - 411
  • [8] Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).
    Khan, Mohammed Ateeb
    Szabados, Bernadett
    Choy, Julia
    Jackson-Spence, Francesca
    Powles, Thomas
    Castellano, Daniel
    Valderrama, Begona P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
    Isoda, Bunpei
    Shiga, Masanobu
    Kandori, Shuya
    Nagumo, Yoshiyuki
    Yoshino, Takayuki
    Ikeda, Atsushi
    Kawahara, Takashi
    Kimura, Tomokazu
    Negoro, Hiromitsu
    Hoshi, Akio
    Mathis, Bryan J.
    Nishiyama, Hiroyuki
    CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 429 - 433
  • [10] A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma
    Urabe, Fumihiko
    Sakanaka, Keigo
    Nakata, Mana
    Goto, Yuma
    Muramoto, Katsuki
    Kadena, Soshi
    Onuma, Hajime
    Iwatani, Kosuke
    Imai, Yu
    Tashiro, Kojiro
    Kimura, Takahiro
    Shimomura, Tatsuya
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2025, : 143 - 146
12345